Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchoscopic local liposomal amphotericin B for refractory invasive pulmonary fungal infection
ChiCTR2600122204Phase 4Not yet recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of liposomal amphotericin b in Acute Invasive Aspergillosis and pulmonary mucormycosis (2 arms), sponsored by Shanxi Bethune Hospital. Primary endpoint: Imaging response rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
Acute Invasive Aspergillosispulmonary mucormycosis
Beyond the preview
Go deeper on ChiCTR2600122204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122204.